MedTrace Logo

Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

NCT00657917 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-01-22

Study results available
· View outcomes & findings →

Summary

The primary objective of this protocol is to treat laboratory confirmed cutaneous leishmaniasis with WR 279,396 in military health care beneficiaries. In this study "cutaneous leishmaniasis" is defined as Old World Leishmaniasis if acquired in the Southwest Central Asia/Middle East.

Conditions

  • Cutaneous Leishmaniasis

Interventions

DRUG

Paromomycin +Gentamicin topical cream

WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.

Sponsors & Collaborators

  • Walter Reed Army Medical Center

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • COL Naomi Aronson, M.D. · Uniformed Services Univ of the Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-20
Primary Completion
2007-06-08
Completion
2010-06-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00657917 on ClinicalTrials.gov